Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Polycythemia Vera 2Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder 1Relapsed Pediatric Solid Tumor 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Peripheral Blood Stem Cell Transplantation 1Lymphoma, Extranodal NK-T-Cell 1Lymphohistiocytosis, Hemophagocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Epstein-Barr Virus Infections 1Colorectal Neoplasms 1Bronchiolitis Obliterans Syndrome 1

Interventions

ruxolitinib 1ponatinib 1Physical Therapy Modalities 1Blood Specimen Collection 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Bronchiolitis Obliterans Syndrome × ruxolitinib × Clear all
NCT05413356 2022-10-19

Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome

First Affiliated Hospital of Zhejiang University

Phase 2 Unknown
50 enrolled
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡